PL2704741T3 - Sposoby postępowania z lekami biologicznymi zawierającymi żywe komórki - Google Patents

Sposoby postępowania z lekami biologicznymi zawierającymi żywe komórki

Info

Publication number
PL2704741T3
PL2704741T3 PL12779413T PL12779413T PL2704741T3 PL 2704741 T3 PL2704741 T3 PL 2704741T3 PL 12779413 T PL12779413 T PL 12779413T PL 12779413 T PL12779413 T PL 12779413T PL 2704741 T3 PL2704741 T3 PL 2704741T3
Authority
PL
Poland
Prior art keywords
handling
live cells
containing live
medicines containing
biological medicines
Prior art date
Application number
PL12779413T
Other languages
English (en)
Inventor
Michael Har-Noy
Original Assignee
Immunovative Therapies, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies, Ltd. filed Critical Immunovative Therapies, Ltd.
Publication of PL2704741T3 publication Critical patent/PL2704741T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10Preservation of living parts
    • A01N1/12Chemical aspects of preservation
    • A01N1/122Preservation or perfusion media
    • A01N1/126Physiologically active agents, e.g. antioxidants or nutrients
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10Preservation of living parts
    • A01N1/14Mechanical aspects of preservation; Apparatus or containers therefor
    • A01N1/146Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving
    • A01N1/148Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving with provisions specially adapted for transporting
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/217IFN-gamma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65BMACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B1/00Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B1/04Methods of, or means for, filling the material into the containers or receptacles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N15/14Optical investigation techniques, e.g. flow cytometry
    • G01N15/149Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866Interferon
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/555Interferons [IFN]
    • G01N2333/57IFN-gamma
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Dermatology (AREA)
PL12779413T 2011-05-03 2012-05-02 Sposoby postępowania z lekami biologicznymi zawierającymi żywe komórki PL2704741T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161481991P 2011-05-03 2011-05-03
US201161528493P 2011-08-29 2011-08-29
US201161565225P 2011-11-30 2011-11-30
US201261582878P 2012-01-04 2012-01-04
EP12779413.9A EP2704741B1 (en) 2011-05-03 2012-05-02 Methods for handling biological drugs containing living cells
PCT/US2012/036103 WO2012151266A1 (en) 2011-05-03 2012-05-02 Methods for handling biological drugs containing living cells

Publications (1)

Publication Number Publication Date
PL2704741T3 true PL2704741T3 (pl) 2018-02-28

Family

ID=47108026

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12779413T PL2704741T3 (pl) 2011-05-03 2012-05-02 Sposoby postępowania z lekami biologicznymi zawierającymi żywe komórki

Country Status (17)

Country Link
US (4) US10350242B2 (pl)
EP (1) EP2704741B1 (pl)
JP (3) JP5934783B2 (pl)
KR (3) KR102229108B1 (pl)
CN (2) CN103732247A (pl)
AU (1) AU2012250794B2 (pl)
BR (1) BR112013028257B1 (pl)
CA (1) CA2838041C (pl)
DK (1) DK2704741T3 (pl)
ES (1) ES2648136T3 (pl)
HU (1) HUE034995T2 (pl)
IL (1) IL229176B (pl)
PH (1) PH12013502253A1 (pl)
PL (1) PL2704741T3 (pl)
PT (1) PT2704741T (pl)
SG (1) SG194774A1 (pl)
WO (1) WO2012151266A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160095307A1 (en) 2014-10-07 2016-04-07 NuTech Medical, Inc. Method and composition for hypothermic storage of placental tissue
WO2016075542A1 (en) * 2014-11-11 2016-05-19 Macrocure, Ltd. Methods for extended storage of activated leukocyte compositions
JP6814593B2 (ja) * 2016-10-14 2021-01-20 株式会社 バイオミメティクスシンパシーズ 幹細胞及び投与システム
IL282735B2 (en) 2018-11-01 2025-10-01 Gracell Biotechnologies Shanghai Co Ltd Preparations and methods for engineering T cells
CN118931967A (zh) * 2018-12-07 2024-11-12 亘喜生物科技(上海)有限公司 用于免疫疗法的组合物和方法
CA3137570A1 (en) * 2019-05-15 2020-11-19 Stemcyte Inc. High concentration cell packaging and shipping
EP4261242A4 (en) 2020-12-10 2024-11-06 Agc Inc. OXYALKYLENE POLYMER, PROCESS FOR PRODUCING SAME, CURABLE COMPOSITION AND CURED PRODUCT
KR20230154796A (ko) 2021-03-12 2023-11-09 에이지씨 가부시키가이샤 경화성 조성물 및 경화물
EP4368671A4 (en) 2021-07-07 2025-07-16 Agc Inc CURABLE COMPOSITION, CURED PRODUCT, ADHESIVE AND SEALANT
WO2023190640A1 (ja) * 2022-03-30 2023-10-05 株式会社カネカ 細胞投与用シリンジを調製する方法、及び細胞投与用シリンジを用いた細胞輸送方法
DE112023002002T5 (de) 2022-04-22 2025-02-20 AGC Inc. Aushärtbare zusammensetzung und ausgehärtetes produkt davon
JPWO2023204067A1 (pl) 2022-04-22 2023-10-26
CN119072501A (zh) 2022-04-27 2024-12-03 Agc株式会社 含反应性硅基团的有机聚合物的制造方法
JPWO2023210582A1 (pl) 2022-04-27 2023-11-02
WO2023233962A1 (ja) 2022-06-03 2023-12-07 Agc株式会社 接着剤組成物及び物品
WO2026009589A1 (ja) 2024-07-05 2026-01-08 Agc株式会社 組成物、反応性ケイ素基を有するポリエーテル化合物の製造方法、ウレタン結合を有するポリエーテル化合物の製造方法、及び重合性不飽和基を有するポリエーテル化合物の製造方法
WO2026009590A1 (ja) 2024-07-05 2026-01-08 Agc株式会社 複合金属シアン化物錯体触媒、ポリエーテル化合物の製造方法、反応性ケイ素基を有するポリエーテル化合物の製造方法、ウレタン結合を有するポリエーテル化合物の製造方法、及び重合性不飽和基を有するポリエーテル化合物の製造方法
WO2026014465A1 (ja) 2024-07-12 2026-01-15 Agc株式会社 ポリエーテル化合物の製造方法、反応性ケイ素基を有するポリエーテル化合物の製造方法、ウレタン結合を有するポリエーテル化合物の製造方法及び重合性不飽和基を有するポリエーテル化合物の製造方法
WO2026014466A1 (ja) 2024-07-12 2026-01-15 Agc株式会社 ポリエーテル化合物の製造方法、反応性ケイ素基を有するポリエーテル化合物の製造方法、ウレタン結合を有するポリエーテル化合物の製造方法及び重合性不飽和基を有するポリエーテル化合物の製造方法
EP4711399A1 (en) 2024-07-12 2026-03-18 Agc Inc. Method for producing polyether compound, method for producing polyether compound having reactive silicon group, method for producing polyether compound having urethane bond, and method for producing polyether compound having polymerizable unsaturated group

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2439003A1 (fr) 1978-10-20 1980-05-16 Anvar Nouvelles pieces d'osteosynthese, leur preparation et leur application
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
AU7873187A (en) 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
PT89121A (pt) 1987-12-04 1989-12-29 Du Pont Processo para a preparacao de interleuquina-2 imobilizada e interleuquina-2 contendo uma extensao no terminal-carboxilo com actividade de interleuquina-2 natural
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6204058B1 (en) 1992-02-07 2001-03-20 Vasogen Ireland Limited Treatment of autoimmune diseases
AU5729294A (en) 1992-11-25 1994-06-22 Tanox Biosystems, Inc. Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
CA2168950A1 (en) 1993-08-06 1995-02-16 Esteban Celis Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl
IL107483A0 (en) 1993-11-03 1994-02-27 Yeda Res & Dev Bone marrow transplantation
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
ES2201177T3 (es) 1995-03-08 2004-03-16 The Scripps Research Institute Sistema de presentacion de antigenos y activacion de celulas-t.
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
DE69737070T2 (de) 1996-05-23 2007-06-21 The Scripps Research Institute, La Jolla Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
CN1237909A (zh) 1996-10-11 1999-12-08 加利福尼亚大学董事会 联合使用肿瘤细胞与混合淋巴细胞的癌症免疫治疗
AU5596898A (en) 1996-12-03 1998-06-29 Osteobiologics, Inc. Biodegradable polymeric film
WO1998033891A1 (en) 1997-01-31 1998-08-06 Hemosol Inc. Method for the production of selected lymphocytes
US7282198B2 (en) * 1997-03-19 2007-10-16 The University Of Arkansas For Medical Sciences Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
ATE412383T1 (de) 1997-05-30 2008-11-15 Osteobiologics Inc Faserverstärkte,poröse,biologisch abbaubare implantatvorrichtung
CA2309206A1 (en) 1997-11-10 1999-05-20 Arch Development Corporation Methods for treatment of tumors and tumor cells using ex vivo activated t cells
JP2001054563A (ja) 1999-07-12 2001-02-27 Isotis Bv 縫合糸
US7112576B1 (en) 1999-12-10 2006-09-26 Regents Of The University Of Minnesota Compositions and methods for cryopreservation of peripheral blood lymphocytes
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
WO2002017935A2 (en) 2000-08-31 2002-03-07 Emory University A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
US6626950B2 (en) 2001-06-28 2003-09-30 Ethicon, Inc. Composite scaffold with post anchor for the repair and regeneration of tissue
WO2003038062A2 (en) 2001-10-31 2003-05-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Generation of use of tc1 and tc2 cells
AU2002351277A1 (en) 2001-12-06 2003-07-09 Georgia Tech Research Corporation Biodegradable, porous structures useful for growing living tissue, and methods of manufacture
US20030170238A1 (en) * 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US20030175272A1 (en) 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
DE10230223A1 (de) 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7371228B2 (en) 2003-09-19 2008-05-13 Medtronic Vascular, Inc. Delivery of therapeutics to treat aneurysms
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
PL2573166T3 (pl) 2004-02-26 2016-11-30 Sposoby otrzymywania komórek T do terapii komórkowej
US7446099B2 (en) 2004-02-27 2008-11-04 Nitto Denko Corporation Compositions and methods for biodegradable polymer-peptide mediated transfection
DK1749090T3 (en) 2004-03-01 2017-09-04 Immunovative Therapies Ltd CELL THERAPY FORMULATION PROCEDURE AND COMPOSITION
CA2557436A1 (en) 2004-03-05 2005-09-29 The Trustees Of Columbia University In The City Of New York Polymer-ceramic-hydrogel composite scaffold for osteochondral repair
TW200726474A (en) 2005-07-15 2007-07-16 Cognate Therapeutics Inc The immunophenotype and immunogenicity of human adipose derived cells
EP1792979A1 (en) * 2005-12-01 2007-06-06 Stiftung Caesar Center of Advanced European Studies and Research Cell culture system for the enrichment and expansion of stem cells
CN101965195A (zh) * 2008-03-05 2011-02-02 巴克斯特国际公司 用于药物投送的组合物和方法

Also Published As

Publication number Publication date
KR20140043367A (ko) 2014-04-09
AU2012250794A1 (en) 2013-12-12
US10350242B2 (en) 2019-07-16
KR102202460B1 (ko) 2021-01-14
BR112013028257A2 (pt) 2017-01-17
AU2012250794A8 (en) 2013-12-19
CA2838041A1 (en) 2012-11-08
CN108261423B (zh) 2021-01-08
US11648273B2 (en) 2023-05-16
JP6006288B2 (ja) 2016-10-12
JP2015091848A (ja) 2015-05-14
HUE034995T2 (en) 2018-05-02
CA2838041C (en) 2018-09-25
CN103732247A (zh) 2014-04-16
EP2704741A1 (en) 2014-03-12
EP2704741A4 (en) 2014-11-19
US20230218672A1 (en) 2023-07-13
JP5934783B2 (ja) 2016-06-15
CN108261423A (zh) 2018-07-10
PT2704741T (pt) 2017-11-24
HK1254754A1 (zh) 2019-07-26
IL229176B (en) 2020-03-31
SG194774A1 (en) 2013-12-30
KR20190090030A (ko) 2019-07-31
US20230226112A1 (en) 2023-07-20
EP2704741B1 (en) 2017-08-23
KR102229108B1 (ko) 2021-03-18
US20190350976A1 (en) 2019-11-21
WO2012151266A1 (en) 2012-11-08
KR20140099328A (ko) 2014-08-11
JP2017039728A (ja) 2017-02-23
US20130101562A1 (en) 2013-04-25
AU2012250794B2 (en) 2015-11-05
BR112013028257B1 (pt) 2020-05-12
PH12013502253A1 (en) 2019-11-29
JP2014517830A (ja) 2014-07-24
JP6359059B2 (ja) 2018-07-18
IL229176A0 (en) 2013-12-31
DK2704741T3 (da) 2017-11-27
ES2648136T3 (es) 2017-12-28

Similar Documents

Publication Publication Date Title
PL2704741T3 (pl) Sposoby postępowania z lekami biologicznymi zawierającymi żywe komórki
IL276012B (en) Pharmaceutical compositions comprising sorbitan esters
EP3375462C0 (en) Improvements to immobilised biological entities
CL2016001190A1 (es) Cultivo de células de mamífero.
EP2681306A4 (en) CELL CULTURE SYSTEM
SMT201500055B (it) Dispositivi e metodi per la coltura di cellule
FI20106121A7 (fi) Soluviljelymateriaali
DK2637954T3 (da) Containerhåndteringssystem
EP2777276A4 (en) Reference picture handling
BR112013012217A2 (pt) incubadora
SI3521208T1 (sl) Kapsula za odmerek s črtno kodo
DK2900806T3 (da) Tredimensionel celledyrkning
EP2727545A4 (en) MEDICAL MANIPULATOR
EP2576376A4 (en) RE-LOCKABLE CONTAINER
HUE037031T2 (hu) Stabil folyékony etanercept készítmény
EP2739233A4 (en) MEDICAL MANIPULATOR
EP2572995A4 (en) TABLETS CASSETTE
EP2732635A4 (en) MULTISENSORIC MANIPULATION
EP2702989A4 (en) STABLE PHARMACEUTICAL COMPOSITION
IL227552B (en) Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
EP2868596A4 (en) CONTAINER
ES1204587Y (es) Envase apilable
DK3144319T3 (da) Cellekultursammensætning indeholdende laminin-521
EP2610945A4 (en) STACK CELL
BR112015003116A2 (pt) preparação farmacêutica sólida contendo levotiroxina